Andy Muschietti says It fans are finally going to get some answers about Pennywise's cryptic backstory in the upcoming ...

While AI coding startups like Cursor close brow-raising rounds on barely three years of existence, Replit's path to a $3 ...

Almost 900 fewer people have been injured on Welsh roads since the default speed limit was lowered from 30 to 20mph. Its introduction in September 2023 cost £34m and was one of the most controversial ...

Many or all of the products here are from our partners that compensate us. It’s how we make money. But our editorial integrity ensures that our product ratings are not influenced by compensation. Citi ...

NEW YORK - September 3, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks ...

DEAR MISS MANNERS: I enjoy having friends and acquaintances from different walks of life, and have found unexpected kinship with people who hold beliefs very different from my own. In other words, I ...

The last time I spoke about Replimune (NASDAQ:REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to ...

DEAR MISS MANNERS: I enjoy having friends and acquaintances from different walks of life, and have found unexpected kinship with people who hold beliefs very different from my own. Related Articles ...

DEAR MISS MANNERS: I enjoy having friends and acquaintances from different walks of life, and have found unexpected kinship with people who hold beliefs very different from my own. Miss Manners: We’d ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...

A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...